-
- Departments
- The Helmsley Cancer Center
- The Nano-Oncological Program
About
The Center for Nano-Oncology operates from the laboratory located in the main building of the hospital on the 5th floor, adjacent to the Genetics Laboratory. The Center for Nano-Oncology focuses on the development of innovative, safe, and effective cancer treatments based on liposomes as carriers for various drugs.
At the helm of the Center for Nano-Oncology is Alberto (Abraham) Gebizone, PhD MD, who is a professor of oncology in the Faculty of Medicine at the Hebrew University. Prof. Gebizone developed the liposomal drug Doxil®, a globally approved treatment for various significant indications in cancer, including breast cancer and ovarian cancer. Currently, the Center for Nano-Oncology is engaged in further developments of liposomal drugs, including an innovative chemotherapeutic-immunotherapeutic formulation known as PLAD, which is in advanced stages of research and development. Additionally, the Center for Nano-Oncology is involved in clinical development of another liposomal drug known as Promitil®, also a creation of Prof. Gebizone, in collaboration with Lipomedix Pharmaceuticals.
In addition to its pure laboratory activities, the Center for Nano-Oncology, under the initiative of Prof. Gebizone and with funding from MERCK, is leading a unique phase 2-1b clinical trial in breast cancer using the drug Doxil and the inhibitor Keytruda®. The Nano-Oncology laboratory includes a liposome production room, a culture room, and a general characterization and analytical testing room. The laboratory activities are supervised by Dr. Hillary Shmida, Ph.D., an experienced researcher in the field of liposomes.